Trypan blue deemed safe in vireoretinal surgery

Article

According to data recently published, trypan blue (TB) doesn't cause injury to the retinal pigment epithelium (RPE) when used in vitreoretinal surgery...

According to data recently published in the Journal Retina, trypan blue (TB) doesn't cause injury to the retinal pigment epithelium (RPE) when used in vitreoretinal surgery.

Dr Ehab Abdelkader et al. from the Grampian University Hospitals-NHS Trust, Aberdeen, UK, examined the in vivo safety of TB in patients treated with TB-assisted internal limiting membrane or epiretinal membrane peeling. The study group comprised 21 eyes of 21 patients that had full-thickness macular hole and/or epiretinal membrane. Distance and near visual acuity (VA) were measured along with amplitude of P50 and N95 of the pattern electroretinogram and fundus autofluorescence preoperatively and 6 and 12 months postoperatively.

The researchers found that there was a statistically significant improvement in distance and near VA as well as P50 and N95 amplitude at both post-op follow-ups. Additionally, autofluorescence analysis proved that there was no damage to the RPE as a result of TB.

Based on the results it was concluded that TB does not cause harmful effects in vitreoretinal surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.